This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
BAD / Bcl2-associated agonist of cell death · IHC design guide
Design Immunohistochemistry for BAD
Plan chromogenic BAD IHC in paraffin sections using the widespread cytoplasmic tissue pattern (HPA tissue IHC). Placental trophoblasts show high staining (HPA tissue IHC), and a human placenta example uses catalog antibody M03520 at 1:50 (datasheet M03520).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
BAD Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining (HPA tissue IHC); mitochondrial outer membrane association expected (UniProt) | |
| Staining pattern | Widespread cytoplasmic staining across tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M03520) | |
| Positive control | Bronchus+4 more · see all | |
| Negative control | Ovary+2 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific) | |
| Caveat | Phosphorylation can shift BAD into the cytoplasm (UniProt) | |
| Regulation | Staining intensity varies among cell types (HPA tissue IHC) | |
| Isoform / epitope | No isoforms or processing annotated; epitope map unknown (UniProt) |
Section 1
Recommended BAD IHC & IF Protocols
The catalog antibody has a datasheet IHC-P protocol (datasheet M03520). The published options below cover rat pulmonary artery BAD, prostate cancer tissue BAD, and rat brain phospho-BAD staining (PMC5442111; PMC11366015; PMC4145317).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M03520) |
| Fixation | Image fixative and duration unreported (datasheet M03520); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M03520); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M03520) |
| Primary antibody | Rabbit monoclonal (clone CHC-2) anti-BAD, 1:50 (datasheet M03520) |
| Primary incubation | Overnight at 4 °C (datasheet M03520) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M03520) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | BAD-positive staining in respiratory epithelial cells of bronchus (HPA tissue IHC: High). HPA tissue profile: Ubiquitous cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet M03520). The cited articles do not specify an EDTA retrieval condition (PMC5442111; PMC11366015; PMC4145317).
Section 2
What Is the Expected BAD Staining Pattern?
BAD is associated with the mitochondrial outer membrane and cytoplasm, and has no transmembrane segment (UniProt Q92934: localization, topology). In paraffin sections, expect cytoplasmic staining in respiratory epithelial cells, kidney tubule cells, neuronal cells and trophoblastic cells (HPA: High in each). HPA describes the tissue pattern as ubiquitous cytoplasmic expression, with Approved IHC reliability, medium consistency with RNA data and pending external verification (HPA: tissue IHC).
| Cytoplasmic signal in bronchial respiratory epithelium or kidney tubules, with recognizable cell boundaries. | This fits the reported IHC pattern: both cell populations stain High (HPA: tissue IHC). Score the named cell population and compartment; the HPA reliability is Approved but pending external verification (HPA: tissue IHC). |
| Strong nuclear-only staining, with little cytoplasmic signal in otherwise intact cells. | Treat this as a localization mismatch, since the reported tissue IHC pattern is cytoplasmic (HPA: tissue IHC). Review counterstain, detection controls and antibody specificity before interpreting nuclear signal as BAD (general IHC practice). |
| Strong staining in ovarian stroma, skeletal myocytes or smooth muscle cells. | These populations were Not detected by HPA IHC (HPA: tissue IHC). Check for cross-reactivity or endogenous detection activity with appropriate controls (general IHC practice); an HPA-negative observation is a comparator, not proof that every specimen must be negative. |
| Diffuse chromogen across cells and surrounding tissue, obscuring compartment boundaries. | The distribution cannot be scored confidently against the reported cytoplasmic pattern (HPA: tissue IHC). Background may arise from nonspecific binding, endogenous enzyme activity or detection chemistry; inspect controls before assigning a cause (general IHC practice). |
| No convincing signal in bronchial respiratory epithelium or kidney tubules. | This conflicts with High staining reported for those cell populations (HPA: tissue IHC). First check that the reference cells are present and the run controls worked, then review the general IHC workflow (general IHC practice). |
💡Expected BAD appearanceCall a result compatible when defined cytoplasmic staining is evident in bronchial respiratory epithelium or kidney tubules at the reported High level (HPA: tissue IHC); nuclear-only staining or widespread, unstructured chromogen is suspect against that pattern (HPA: tissue IHC; general IHC practice).
| Tissue and cell selection | Bronchial respiratory epithelial cells, kidney tubule cells, caudate neuronal cells and placental trophoblastic cells are High comparators (HPA: tissue IHC). Ovarian stroma, skeletal myocytes and smooth muscle cells were Not detected; assess the specified cells, not whole-section darkness (HPA: tissue IHC). |
| Compartment and phosphorylation | BAD is annotated at the mitochondrial outer membrane and in cytoplasm; phosphorylated BAD locates to cytoplasm (UniProt Q92934: localization). Thus cytoplasmic IHC is compatible with the record, while this section cannot determine BAD phosphorylation state from total staining (UniProt Q92934: modified residues; general IHC interpretation). |
| Antibody evidence | Three listed antibodies have Approved IHC status, while the tissue profile has medium consistency with RNA data and awaits external verification (HPA: antibodies; tissue IHC). Use that qualification when judging an unexpected compartment or cell population; Approved does not settle specimen-level specificity (HPA: tissue IHC; general IHC interpretation). |
| IHC versus IF localization | HPA reports mainly mitochondrial ICC-IF localization with an enhanced main location; its additional principal-piece and end-piece locations are uncertain (HPA: subcellular). Use the tissue IHC cytoplasmic profile to score paraffin chromogenic sections; do not require mitochondria to resolve as individual structures in IHC (HPA: tissue IHC; general IHC practice). |
| Situation | Likely cause | Next action |
|---|---|---|
| High-background section with weak contrast in the target cells. | Nonspecific reagent binding or endogenous chromogenic activity is possible (general IHC practice). | Compare a no-primary control, review blocking and detection steps, and adjust antibody concentration within the validated IHC workflow (general IHC practice). |
| Nuclear-only signal persists across multiple tissues. | It conflicts with the reported cytoplasmic IHC profile (HPA: tissue IHC); the cause is unresolved. | Check counterstain interpretation and no-primary control, then compare staining with another IHC-Approved antibody if available (general IHC practice; HPA: antibodies). |
| No staining in a reference-positive area. | Bronchial respiratory epithelium and kidney tubules were High in HPA IHC (HPA: tissue IHC); a failed run or sampling difference remains possible. | Confirm the named cells are present, inspect run controls, and review retrieval, dilution and detection settings as general IHC variables (general IHC practice). |
| Unexpected strong signal in skeletal myocytes or smooth muscle cells. | Those cell types were Not detected in HPA IHC (HPA: tissue IHC); cross-reactivity or endogenous activity is possible (general IHC practice). | Compare no-primary and detection controls, then verify the cell identity and repeat with a second IHC-Approved antibody if available (general IHC practice; HPA: antibodies). |
| Punctate staining is absent, but cytoplasmic staining is clear. | HPA tissue IHC describes ubiquitous cytoplasmic expression, while HPA ICC-IF reports mainly mitochondrial localization (HPA: tissue IHC; subcellular). | Score the chromogenic section against its cytoplasmic IHC pattern and cell types; record any compartment uncertainty instead of demanding IF-level detail (HPA: tissue IHC; general IHC practice). |
| IF/ICC question: should this IHC result be judged by the same visible pattern as an IF image? | The assays report different views: cytoplasmic tissue IHC and mainly mitochondrial ICC-IF (HPA: tissue IHC; subcellular). | Answer: evaluate each against its own HPA application evidence; treat the uncertain additional IF locations cautiously (HPA: subcellular). |
Experiment evidence
IHC & IF images showing BAD staining
M03520 · IHCIHC analysis of BAD using anti-BAD antibody (M03520). BAD was detected in a paraffin-embedded section of human breast cancer tissue. Heat me
M03520 · IHCIHC analysis of BAD using anti-BAD antibody (M03520). BAD was detected in a paraffin-embedded section of human placenta tissue. Heat mediate
M03520 · IFImmunofluorescent analysis of Hela cells, using Bad Antibody .
M03520-1 · IHCRat kidney was stained with anti-Bad rabbit antibody
M03520-1 · IHCHuman kidney was stained with anti-Bad rabbit antibody
A03520 · IHCImmunohistochemical staining of rat thymus using Bad at 2 μg/mL.
A03520 · IFImmunofluorescence of BAD in Rat Thymus cells with BAD antibody at 10 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000002330-BAD/tissue/cerebral+cortex#imid_1393436
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000002330-BAD/tissue/colon#imid_7310006
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000002330-BAD/tissue/liver#imid_7310007
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000002330-BAD/tissue/kidney#imid_7310000
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA028185; green = BAD, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA028185; green = BAD, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for BAD IHC & IF
🧪Run bronchus first: respiratory epithelial cells should stain (HPA: High in bronchus respiratory epithelial cells). Use skeletal muscle as the negative tissue, focusing on myocytes (HPA: Not detected in skeletal muscle myocytes); on the bronchus slide, internal background-reference cells should retain visible counterstained nuclei without specific DAB signal, but no bronchial cell type is documented here as BAD-negative.
Positive control tissue: Bronchus (Respiratory epithelial cells, HPA High)
Negative control tissue: Ovary (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show BAD in A-431, U-251MG, U2OS, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), Sperm, with annotated localisation: Mitochondria (enhanced) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a concentration-matched nonimmune rabbit IgG isotype control matched to the primary antibody’s clonality (caption: rabbit anti-BAD primary; standard IHC practice). Confirm specificity with BAD knockout material or a validated immunizing-peptide block (standard IHC practice). Quench endogenous peroxidase in bronchus before HRP/DAB detection; block endogenous biotin if using avidin–biotin detection (caption: HRP/DAB detection; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected M03520 paraffin-section caption does not state its fixative (caption: fixative not stated). The caption uses heat retrieval in EDTA at pH 8.0 for breast cancer tissue, but whether bronchus requires that retrieval condition is unreported (caption: EDTA retrieval in breast cancer). The supplied evidence does not establish that frozen sections or IF are easier; for IF, mitochondrial staining is a localization check, while bronchial autofluorescence should be assessed with an unstained control (HPA: enhanced mitochondrial ICC-IF localization; standard IF practice).
HPA tissue IHC evidence for BAD
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Caudate | Neuronal cells | High | Protein (IHC) | HPA → |
| Kidney | Cells in tubules | High | Protein (IHC) | HPA → |
| Nasopharynx | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Placenta | Trophoblastic cells | High | Protein (IHC) | HPA → |
Section 3
Advanced BAD IHC Tips
Troubleshoot BAD staining in paraffin sections by checking retrieval, cellular distribution, controls and scoring against the documented IHC conditions.
How should I optimize retrieval when BAD staining is weak in paraffin sections?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0 (datasheet M03520). Keep heating and cooling conditions consistent across sections, then compare a retrieved section with a no-retrieval control to judge whether retrieval improves specific staining (standard IHC practice). The documented paraffin-section example used the catalog antibody at 1:50 overnight at 4°C, so hold those conditions steady while assessing retrieval (datasheet M03520). Include a section expected to stain in the same run, such as kidney tubules, which show high BAD staining in the reference profile (HPA: High in kidney tubule cells). If signal remains weak, test an alternative retrieval condition as a separately controlled experiment (standard IHC practice).
Could fixation explain variable BAD staining between paraffin blocks?
The selected paraffin-section caption does not state a fixative, so BAD-specific fixation sensitivity is unknown (datasheet M03520: fixative not stated). Record each block's fixative and fixation history before comparing staining across specimens, and process matched sections together where possible (standard IHC practice). Excessive or uneven fixation can alter antibody access in IHC generally, but the supplied evidence does not establish which fixation conditions preserve this antibody's BAD epitope (standard IHC practice; datasheet M03520: fixative not stated). Keep retrieval at EDTA pH 8.0 while comparing blocks so retrieval changes do not obscure the fixation comparison (datasheet M03520). Use a same-run reference section and report any persistent block-dependent differences (standard IHC practice).
What cellular staining pattern is plausible for BAD in chromogenic IHC?
Assess BAD primarily as cytoplasmic staining in tissue sections, while allowing a mitochondrial pattern when resolution permits (HPA tissue IHC: ubiquitous cytoplasmic expression; UniProt Q92934: cytoplasm and mitochondrial outer membrane). BAD has no annotated transmembrane segment, so a sharply defined plasma-membrane pattern is not established by its recorded topology (UniProt Q92934 topology). Phosphorylation can shift BAD toward the cytoplasm, meaning a change in distribution may have biological context but cannot be assigned to phosphorylation from total-BAD staining alone (UniProt Q92934: subcellular location and phosphoserines). Compare the same cell type across sections at similar counterstain and DAB intensity (standard IHC practice). Treat a purely nuclear signal as a specificity question requiring controls (UniProt Q92934: subcellular location; standard IHC practice).
How do BAD isoforms and modifications affect antibody interpretation?
The supplied BAD record lists 0 isoforms, so it provides no basis for assigning distinct tissue staining patterns to named isoforms (UniProt Q92934: isoforms). BAD has annotated phosphoserines at 25, 75 and 91, plus an arginine modification at 94; their effect on this antibody's binding is not specified (UniProt Q92934: modified residues; datasheet M03520: epitope not stated). Check the antibody's documented epitope and whether it recognizes modified BAD before making modification-specific claims (standard IHC practice). If that information is unavailable, describe staining as antibody-detected BAD rather than a particular phosphorylation state (standard IHC practice). Compare treated and control sections under identical retrieval and detection conditions to assess reproducibility (standard IHC practice).
How can I assess BAD localisation with immunofluorescence alongside this IHC guide?
For a separate IF experiment, pair BAD with a mitochondrial marker and a marker for the cell type being assessed; BAD is recorded at the mitochondrial outer membrane and in the cytoplasm (UniProt Q92934: subcellular location; standard IF practice). Choose fluorophores after checking the specimen's autofluorescence, and keep single-label controls to distinguish bleed-through from colocalisation (standard IF practice). Permeabilise sufficiently to reach intracellular BAD, then adjust detergent exposure to preserve mitochondrial structure; the antibody epitope's membrane-facing side is not supplied (UniProt Q92934: subcellular location; standard IF practice). HPA reports mainly mitochondrial localisation in its subcellular imaging, which offers a comparison pattern rather than validation of the catalog antibody for IF (HPA subcellular; datasheet M03520: paraffin-section IHC).
What should I check when BAD IHC shows diffuse brown background?
Start by comparing a no-primary control with the stained section to identify signal from secondary detection, endogenous peroxidase or chromogen deposition (standard IHC practice). The documented paraffin-section example used 10% goat serum blocking and DAB detection, providing a starting point for reproducing its workflow (datasheet M03520). Apply a peroxidase block and inspect wash quality, section edges and drying artefacts when background persists (standard IHC practice). BAD's broad cytoplasmic tissue expression means diffuse staining is not automatically nonspecific, so compare cellular detail and intensity with same-run controls (HPA tissue IHC: ubiquitous cytoplasmic expression; standard IHC practice). Titrate antibody exposure only after checking these controls, recording each changed condition (standard IHC practice).
How should I quantify BAD staining across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and tissue region before scoring, then report either percentage of positive cells, an H-score, or positive-cell density per mm² according to the study question (standard IHC practice). For an H-score, record the fractions at intensity 0–3 and sum each percentage multiplied by its intensity, giving a 0–300 scale (standard IHC practice). Normalize counts to viable tissue area or the number of eligible cells, and apply identical thresholds, counterstain settings and exclusion rules across sections (standard IHC practice). BAD staining varies by cell population in the reference profile, including high kidney tubule staining and undetected skeletal-muscle myocytes, so avoid pooling unlike cell types (HPA tissue IHC). Report scorer agreement when visual grading is used (standard IHC practice).
How do I distinguish plausible BAD staining from artefact?
Look for cellular cytoplasmic signal with a plausible mitochondrial distribution, consistent with BAD's recorded locations and the tissue IHC profile (UniProt Q92934: subcellular location; HPA tissue IHC: ubiquitous cytoplasmic expression). Compare the signal with expected cell populations: kidney tubule cells are reported high, whereas ovarian stroma cells are reported undetected (HPA tissue IHC). Strong staining confined to section edges, necrotic regions or a no-primary control warrants investigation for processing or detection artefact (standard IHC practice). Check endogenous peroxidase activity before attributing brown DAB deposits to BAD (standard IHC practice). The HPA tissue profile is approved with medium staining-to-RNA consistency and pending external verification, so corroborate consequential findings with independent evidence (HPA tissue IHC: reliability).
Boster reagents
Best BAD / Bcl2-associated agonist of cell death IHC Antibodies
Catalog IHC figures cover human breast cancer, placenta and kidney; mouse small intestine and kidney; and rat kidney and thymus. IF figures show HeLa and rat thymus cells (catalog image captions).
Real IHC data
Anti-Bad Rabbit Monoclonal Antibody
Cat # M03520
Real IHC data
Anti-Bad Rabbit Monoclonal Antibody
Cat # M03520-1
Real IHC data
Anti-BAD Antibody
Cat # A03520
M03520 shows IHC in paraffin-embedded human breast cancer and placenta and mouse small intestine, plus IF in HeLa cells; M03520-1 shows IHC in human, mouse and rat kidney (M03520 and M03520-1 image captions). A03520 shows IHC in rat thymus and IF in rat thymus cells; all three list human, mouse and rat reactivity (A03520 image captions; catalog reactivity).
Which to pick: For paraffin-section IHC, choose M03520: its human breast cancer caption documents EDTA retrieval at pH 8.0 and a 1:50 primary dilution; the fixative is unreported (M03520 IHC caption). For IF/ICC, choose M03520 because it lists both applications and has a HeLa IF figure (M03520 applications and IF caption). For IHC across human, mouse and rat tissues, choose M03520-1: its kidney captions cover each species, and the catalog describes it as a recombinant rabbit monoclonal (M03520-1 IHC captions and description).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q92934 (BAD_HUMAN, Bcl2-associated agonist of cell death).
- Human Protein Atlas. BAD tissue IHC expression (reliability: Approved).
- Human Protein Atlas. BAD subcellular location (ICC-IF): Mainly localized to the mitochondria. In addition localized to the principal piece and end piece..
- Human Protein Atlas. BAD antibody validation summary (3 antibodies).
- Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer. OncoTargets and therapy 2013 — PMC3787924.
- Role of FoxO1 and apoptosis in pulmonary vascular remolding in a rat model of chronic thromboembolic pulmonary hypertension. Scientific reports 2017 — PMC5442111.
- Digital spatial profiling identifies the tumor center as a topological niche in prostate cancer characterized by an upregulation of BAD. Scientific reports 2024 — PMC11366015.
- Astaxanthin alleviates early brain injury following subarachnoid hemorrhage in rats: possible involvement of Akt/bad signaling. Marine drugs 2014 — PMC4145317.
- PubMed PMID:8929532 — UniProt-cited evidence.
- PubMed PMID:9388232 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for BAD (Bcl2-associated agonist of cell death). Expected localisation Cytoplasmic staining (HPA tissue IHC); mitochondrial outer membrane association expected (UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M03520). Validated IHC antibody: M03520 at 1:50 (the product's own IHC validation image is shown). Controls (HPA): positive Bronchus (Respiratory epithelial cells); negative Ovary. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M03520); 2. Fixation: Image fixative and duration unreported (datasheet M03520); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M03520); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M03520); 8. Primary antibody: Rabbit monoclonal (clone CHC-2) anti-BAD, 1:50 (datasheet M03520); 9. Primary incubation: Overnight at 4 °C (datasheet M03520). Watch for: Fixation: Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); Caveat: Phosphorylation can shift BAD into the cytoplasm (UniProt); Isoform / epitope: No isoforms or processing annotated; epitope map unknown (UniProt); Regulation: Staining intensity varies among cell types (HPA tissue IHC). Evidence: UniProt Q92934, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the mitochondria. In addition localized to the…, Datasheet M03520, PMC5442111, PMC11366015. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/BAD/immunohistochemistry-ihc-guide.